|
|
||||||||
Sign In to gain access to subscriptions and/or personal tools. |
|||||||||
PHARMACOKINETICS AND PHARMACODYNAMICS |
From GlaxoSmithKline, Research Triangle Park, North Carolina (Dr. Shelton); the Antiviral Clinical Pharmacology Unit (Dr. Hewitt, Dr. Morse), Immunodeficiency Services Clinic, Erie County Medical Center and the Laboratory for Antiviral Research (Dr. Hewitt, Dr. Morse), Departments of Pharmacy Practice and Medicine, University at Buffalo, Buffalo, New York and PharmaResearch Corporation, Morrisville, North Carolina (Dr. Adams); and Pharmacia and Upjohn, Inc., Kalamazoo, Michigan (Dr. Cox, Mr. Chambers)
To determine the impact of gastric hypoacidity and acidic beverages on
delavirdine mesylate pharmacokinetics in HIV-infected subjects, matched
subjects with (n = 11) and without (n = 10) gastric hypoacidity received
delavirdine 400 mg tid with either water or an acidic beverage (usually orange
juice). The pharmacokinetics of delavirdine and its N-desalkyl metabolite were
determined over 8 hours after 14 days of each treatment. Gastric pH was
measured at baseline and during each pharmacokinetic evaluation. Delavirdine
exposure (Cmax, AUC0
8h, and
Cmin) was 50% lower and the extent of delavirdine metabolism was
higher in subjects with gastric hypoacidity. Orange juice produced a lower
mean gastric pH compared to water and increased delavirdine absorption by 50%
to 70% in subjects with gastric hypoacidity. However, orange juice had a
marginal impact on delavirdine exposure in subjects without gastric
hypoacidity. HIV-infected subjects with gastric hypoacidity significantly
malabsorb delavirdine. Delavirdine administration with acidic beverages
improves, but does not normalize, absorption in these subjects.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |